Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Key target for Foot and Mouth drug revealed

21.03.2005


A complete picture of Foot-and-Mouth Disease’s key replication enzyme could lead to the development of new drugs to control the disease without recourse to vaccination or slaughter, scientists report today.



By solving the structure of the Foot-and-Mouth Disease Virus (FMDV) enzyme named ’3C protease’ scientists have taken an essential step towards developing protease inhibitors, a class of anti-viral drug that has proved hugely successful in controlling HIV.

The structure paves the way for their development by revealing the atomic details of the key viral enzyme that would serve as a target for drugs.


3C protease’s function is to help the virus replicate itself. A drug that binds and inhibits FMDV 3C protease would stop its spread by blocking its replication and thus its ability to infect a herd.

"In an outbreak we would ’dose up’ the animals and in theory they would be protected immediately," said Dr Stephen Curry of Imperial College London and senior author of the research paper, published in Journal of Biological Chemistry this week. "In contrast, vaccines take several days to have effect and that allows further spread of the disease."

"Our work is a very first step in developing an effective drug to do this. We can see what the enzyme looks like and it gives us an idea of what sort of shapes and types of molecule could bind specifically to the enzyme and block it."

The Imperial researchers are now designing a molecule to act as an inhibitor.

Together with Professor Robin Leatherbarrow of the Department of Chemistry, Dr Curry’s team from the Division of Cell and Molecular Biology has probed the specificity of the 3C enzyme in the hope of developing peptide-like inhibitors, similar to those successful in tackling HIV. Professor Leatherbarrow is mapping out the key amino acid sequences that the protease snips in-between, a process called ’peptide cleavage analysis’.

"We’ve determined the key features of peptides that are recognised by the FMDV 3C protease. Now we can start working on making the inhibitors," said Dr Curry.

During the devastating outbreak of Foot-and-Mouth in the UK in 2001, there was much debate as to whether vaccines should be used to control the disease. They were not deployed and the government relied on mass slaughter of five million animals to bring the epidemic under control.

Protease inhibitors were developed against HIV in the 1980s and 1990s, the first going on sale in 1996. However, interactions between the drugs and the HIV virus have given rise to drug-resistant strains, reducing the treatment’s effectiveness.

Although the same strategy is being adopted, Dr Curry does not foresee the same happening with an FMDV protease inhibitor due to the intrinsic differences between the diseases:

"HIV is a very long term infection, taking 10-15 years to overwhelm the body. That gives the virus plenty of time to develop resistance to anti-viral drugs. FMDV is highly contagious, much easier to get than HIV, and has a rapid onset, which is why outbreaks tend to spread so rapidly," said Dr Curry. "If you wanted to control an FMDV outbreak you could in theory swamp the livestock population with anti-viral drugs for a few weeks and hopefully eradicate the outbreak very quickly."

The 23,000 Dalton (weight) enzyme, is made of 213 amino acids, and is folded into a classic protease form, similar to those seen in poliovirus, hepatitis A virus and human rhinovirus, the major cause of the common cold.

The structure took over four years to solve, the start of research pre-dating the 2001 Foot-and-Mouth outbreak. The greatest problems came in making crystals of the 3C protease so that its structure could be solved by X-ray crystallography -- a particularly taxing task to solve for then beginning PhD student and first author of this paper, Dr James Birtley.

The work was supported by the Biological and Biotechnological Sciences Research Council, the Fleming Fund (Imperial College London), and the Medical Research Council.

Tom Miller | alfa
Further information:
http://www.imperial.ac.uk

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>